In a manufacturing setting, our Viral Sensitizers can result in cheaper and more productive processes to manufacture vaccines and other virus-based products.
By developing process-tailored Viral Sensitizer formulations, we have achieved exponential improvements in yield for a range of viruses and common cell lines and production methods used for vaccine or viral vector manufacturing (e.g., Vero, MRC-5, HEK-293). Improvements in yield can range from two to one-hundred-fold.
We can tailor formulations of our Viral Sensitizers to boost virus yield in your manufacturing facility.
Viral vectors are commonly used to infect cells isolated from patients or other sources to generate effective cellular therapies (e.g CAR-T).
By preventing the destruction of viral vectors by the natural defences of cells, our Viral Sensitizers can facilitate infection and help reduce the high costs of production of these highly promising therapies.
We are developing specialized Viral Sensitizer formulations for cell therapy applications using AAV, Lentivirus, and Adenovirus and can partner with you for your specific product or indication.
THERAPIES AS PART OF VIRAL PRODUCTS
When included as part of a viral product, viral sensitizers can enhance therapeutic effects.
For example, Viral Sensitizers safely enhance oncolytic virus cancer therapy by momentarily altering the tumor's immune response. This enables more effective tumor infection and destruction of cancer cells.
The expression of therapeutic
transgenes can improve when using Viral Sensitizers in conjunction with gene therapy vectors.
We have more than a decade of experience combining our small molecules with therapeutic viruses and can partner with you to improve the effects of your therapies.